Page 3 - Paul Cremer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis -
- Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation and death at Day 29; Phase 3 enrollment ongoing -
- Final KPL-404 Phase 1 data support further development in patients; Phase 2 proof-of-concept trial initiation planned for 2H 2021 -
- Cash reserves of approximately $264 million -
HAMILTON, Bermuda, May 04, 2021 (GLOBE NEWSWIRE) Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today reported first quarter 2021 financial results and recent corporate and portfolio activity. ....

United States , Mark Ragosa , Sanjk Patel , Paul Cremer , Antonio Brucato , Regeneron Pharmaceuticals , Department Of Biomedical , Regeneron Pharmaceuticals Inc , American College Of Cardiology , Drug Administration , Exchange Commission , Kiniksa Pharmaceuticals Ltd , Department Of Cardiovascular Medicine , University Of Milan , Chief Executive Officer , Worst Itch Numeric Rating Scale , American College , Clinical Science , Fatebenefratelli Hospital , Cardiovascular Medicine , Cleveland Clinic , Orphan Drug , Breakthrough Therapy , Private Securities Litigation Reform Act , Annual Report , ஒன்றுபட்டது மாநிலங்களில் ,